Gynecologic and Obstetric Investigation
Session 3
Benefit of GnRH Analogue Pretreatment for Hysteroscopic Surgery in Patients with Bleeding DisordersRömer T.Department of Obstetrics and Gynecology, University Hospital, Ernst Moritz Arndt University, Greifswald, Germany
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: May 15, 1998
Issue release date: May 1998
Number of Print Pages: 10
Number of Figures: 6
Number of Tables: 11
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Abstract
Hysteroscopic surgery is widely used for the treatment of patients suffering from menorrhagia. In different studies, pretreatment of the endometrium with GnRH analogues (GnRH-a) prior to endometrial ablation has been reported to increase the success rate, as well as to reduce the menstrual blood flow, accounting for a significantly higher postoperative amenorrhea rate (42% in pretreated patients vs. 24% in those receiving no pretreatment). The aim of pretreatment is not only to obtain a thin endometrium but also to reduce the size and vascularization of myomas being treated. In our study, GnRH-a administration prior to endometrial ablation was shown to have the following advantages: improved hysteroscopic view, reduced blood loss, absorption of uterine distending fluid and higher postoperative amenorrhea rates. Prior to hysteroscopic myoma resection, pretreatment with GnRH-a may be particularly indicated for all myomas with a diameter of more than 3 cm and/or with an intramural portion, or for patients suffering from secondary anemia. GnRH-a pretreatment is thus indicated before endometrial ablation, and in most cases, before hysteroscopic resection of submucous myomas, and combined medical and surgical therapy has clear benefits in the treatment of bleeding disorders.
Related Articles:
References
- Derman SG, Rehnstrom J, Neuwirth RS: The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol 1991;77:591–594.
-
Goldrath MH, Fuller TA, Segal S: Laser photovaporization of endometrium for the treatment of menorrhagia. Am J Obstet Gynecol 1981;104:14–19.
- Römer Th: Die transzervikale Endometriumablation mit der Roller-Ball-Methode – Eine Alternative zur Hysterektomie bei therapieresistenten Hypermenorrhoen. Erste Erfahrungen. Geburtshilfe Frauenheilkd 1994;54:213–215.
-
Römer Th, Straube W: Operative Hysteroscopy – A Practical Guide, ed 1. Berlin-New York, de Gruyter, 1997.
-
Mencaglia L, van Herendael BJ, Tantini C, Marabini A: Evaluation of benefits for the patients of hysteroscopic myoma resection. Gynaecol Endosc 1994;3:177–179.
- Römer Th: Die hysteroskopische Myomresektion von submukösen Myomen mit überwiegend intramuraler Komponente. Zentralbl Gynäkol 1997;119:374–377.
-
Donnez J, Nisolle M, Clerckx F, Casanas Roux F, Saussoy P, Gillerot S: Advanced endoscopic techniques used in dysfunctional bleeding, fibroids and endometriosis and the role of gonadotropin-releasing hormone agonist treatment. Br J Obstet Gynaecol 1994;101(suppl 10):2–9.
- Brooks PG, Clouse J, Mornis LS: Hysterectomy vs. resectoscopic endometrial ablation for the control of abdominal uterine bleeding – A comparative study. J Reprod Med 1994;39:755–760.
- Brooks P: Hysteroscopic surgery using the resectoscope: Myomas, ablation, septae and synechiae: Does pre-operative medication help? Clin Obstet Gynecol 1992;35:249–255.
-
Scottish Hysteroscopy Audit Group: A Scottish audit of hysteroscopic surgery for menorrhagia. Br J Obstet Gynaecol 1993;100:249–254.
- Brooks PG, Serden SP: Endometrium ablation with a single dose of leuprolide acetate depot. J Reprod Med 1991;36:477–478.
-
Vercellini P, Trespidi L, Bramante T, Panazza S, Mauro F, Crosignani PG: Gonadotropin releasing hormone agonist treatment before hysteroscopic endometrial resection. Int J Obstet Gynecol 1994;45:235–239.
-
Garry R, Khair A, Mooney P, Stuart M: A comparison of goserelin and danazol as endometrial thinning agents prior to endometrial laser ablation. Br J Obstet Gynaecol 1996;103:691–694.
- Perino A, Chianchiano N, Petriono M, Cittadini E: Role of leuprolide acetate depot in hysteroscopic surgery: A controlled study. Fertil Steril 1993;59:507–510.
-
Römer Th: Hysteroskopische Therapie rezidivierender Blutungsstörungen unter Antikoagulationdauertherapie. Zentralbl Gynäkol 1994;116:659–661.
-
Römer Th, Schwesinger G: Hormonal inhibition of endometrium for transcervical endometrial ablation – A prospective study with a 2-year follow-up. Eur J Obstet Gynecol 1997;74:201–203.
- Petrucco OM, Fraser IS: The potential for the use of GnRH agonist for treatment of dysfunctional uterine bleeding. Br J Obstet Gynaecol 1992;99:34–36.
- Fraser IS, Healy DL, Torode H, Song JY, Mamers P, Wilde F: Depot goserelin and danazol pre-treatment before roller-ball endometrial ablation for menorrhagia. Obstet Gynecol 1996;87:544–550.
-
Sowter MC, Bidgood K, Richardson JA: A prospective randomized trial of the effect of preoperative endometrial inhibition on the long-term outcome of transcervical endometrial resection. Gynaecol Endosc 1997;6:33–37.
-
Nicholson SL, Slade RJ, Ahmed AIH, Gillmer MDG: Endometrial resection in Oxford: The first 500 cases – A 5-years follow-up. J Obstet Gynecol 1995;15:38–43.
- Istre O, Forman A, Bourne TH: The relationship between preoperative endometrial thickness, the anteroposterior diameter of the uterus and clinical outcome following transcervical resection of the endometrium. Ultrasound Obstet Gynecol 1996; 8:412–416.
- Taskin O, Yalcinoglu A, Kucuk S, Burak F, Ozekici V, Whealer JM: The degree of fluid absorption during hysteroscopic surgery in patients pre-treatment with goserelin. J Am Assoc Gynecol Laparosc 1996;3:555–559.
-
Wamsteker K: Classification of submucous myoma. ESH Membership Directory, 1992, pp 25–32.
- Benagiano G, Cronje H, Kirvinen ST, Klintorp S, Fadini R, van der Spuy ZM: Zoladex (goserelin acetate) and the anemic patient: Results of a multicenter fibroid study. Fertil Steril 1996;66:223–229.
-
Römer Th: Zum Wert der Vorbehandlung mit Gonadotropin-Releasing-Hormon-Agonisten vor der transzervikalen Resektion solitärer submuköser Myome. Gynäkol Geburtshilfliche Rundsch 1996;36:34–36.
- Higashijima T, Kataoka A, Nishida T, Yakushiji M: Gonadotropin-releasing hormone agonist therapy induces apoptosis in uterine leiomyoma. Eur J Obstet Gynecol Reprod Biol 1996;68:169–173.
- Gutman JN, Thornton KL, Diamond MP, Carcangir ML: Evaluation of leuprolide acetate treatment on histopathology of uterine myomata. Fertil Steril 1994; 61:622–626.
- Friedman AJ, Fine C, Daly M, Rein MS, Juneau-Norcross M: Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo. Fertil Steril 1992;58:205–208.
- Vavala V, Lanzone A, Monaco A, Scribani A, Guida C, Mancuso S: Postoperative GnRH-analog treatment for the prevention of recurrence of uterine myomas after myomectomy. Gynecol Obstet Invest 1997;43:251–254.
-
Friberg B, Peterson F, Willen R, Ahlgren M: A new technique for endometrial destruction by thermal coagulation. Gynaecol Endosc 1995;4(suppl 1):27.
- Vilos GA, Vilos EC, Pendley L: Endometrial ablation with a thermal balloon for the treatment of menorrhagia. J Am Assoc Gynecol Laparosc 1996;3:383–387.
- Goldrath MH, Barrionuero M, Husain M: Endometrial ablation by hysteroscopic instillation of hot saline solution. J Am Assoc Gynecol Laparosc 1997;4:235–240.
- Brooks PG: Resectoscopic myoma vaporizer. J Reprod Med 1995;40:791–795.
Article / Publication Details
Published online: May 15, 1998
Issue release date: May 1998
Number of Print Pages: 10
Number of Figures: 6
Number of Tables: 11
ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)
For additional information: https://www.karger.com/GOI
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
PubMed ID
